Editorial Office, Journal of Microbiology and Biotechnology Reports, United Kingdom

Publications

• Commentary   
  Antiviral targets for hepatitis C and molecular virology
  Author(s): James Smith*
  
  Approximately 170 million people worldwide have the Hepatitis C Virus (HCV). Antiviral therapy with pegylated interferon alfa and ribavirin as a combination is the foundation for preventing HCV infection sequelae. To identify infection, direct treatment choices, and gauge the virological response to antiviral therapy, the use of serological and virological assays has grown to be crucial in the management of HCV infection. For the diagnosis of acute and chronic hepatitis C, anti-HCV antibody and HCV RNA tests are employed. Since the HCV genotype affects the indication, the course of treatment, the dosage of ribavirin, and the method of virological surveillance, it is important to systematically determine the genotype before starting treatment. Hepatocellular carcinoma and liver cirrhosis are primarily brought on by chronic hepatitis C globally. Although there are few treatment opt.. Read More»
  DOI: 10.37532/puljmbr.2022.5(6).68

  • Abstract
  • Full-Text
  • PDF